Key result
Very low-dose rivaroxaban reduced thrombus formation and platelet-dependent thrombin generation in patients with ACS receiving DAPT, particularly in clopidogrel nonresponders.
Why the study?
Does very low-dose rivaroxaban reduce thrombus formation and platelet-dependent thrombin generation in patients with ACS receiving DAPT?
RCT
Does very low-dose rivaroxaban reduce thrombus formation and platelet-dependent thrombin generation in patients with ACS receiving DAPT?
Adjunctive very low-dose rivaroxaban reduces thrombus formation and platelet-dependent thrombin generation in ACS patients on DAPT, suggesting a potential mechanism for ischemic benefit.
No takes yet. Share an insight, caveat, or question.
Selective platelet marker effects with adjunctive VLD rivaroxaban on P2Y12 therapy; hypothesis-generating, should not change practice.
Borst et al. (2018) conducted an RCT in Non-ST-elevation myocardial infarction (ACS). Very low-dose rivaroxaban was evaluated on Thrombus formation and platelet-dependent thrombin generation. Very low-dose rivaroxaban reduced thrombus formation and platelet-dependent thrombin generation in patients with ACS receiving DAPT, particularly in clopidogrel nonresponders.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: